Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07423897 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Consumer Health Study Aims to Evaluate the Safety, Tolerability and Impact of ED02 Probiotic Supplement on Gastrointestinal Outcomes

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 1, 2026 (before its estimated June 17, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status changed: Not Yet Recruiting → Active, Not Recruiting
    • Start date changed from estimate of Mar 4, 2026 to Feb 2, 2026
    • Site contact updated
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The Study Team identified Bifidobacterium pseudocatenulatum ED02 as a safe and effective probiotic strain isolated from a healthy human donor. Research by the Study Team indicates that this strain lacks harmful genetic traits and can successfully mitigate infections from hypervirulent pathogens like Klebsiella pneumoniae without adverse effects.
Trial Details
NCT Number NCT07423897
Lead Sponsor Synbiotic Health
Collaborators: People Science, Inc.
Conditions
(from sponsor)		 Gastrointestinal, Gut Health
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov